Tiziana Adage

Dr. Tiziana Adage

BIT Pharma GmbH

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Cytokine
Verified
Journal Article
Closed access
MGMartha Gschwandtner
Martha Gschwandtner
ESElisabeth Strutzmann
Elisabeth Strutzmann
MTMauro Martins Teixeira
Mauro Martins Teixeira
HAHans-Joachim Anders
Hans-Joachim Anders
MDMaria Diedrichs-Möhring
Maria Diedrichs-Möhring
AKAndreas Kungl
Andreas Kungl

21 January 2016 in Neoplasia
Verified
Journal Article
Open access
MRMarko Roblek
Marko Roblek
ESElisabeth Strutzmann
Elisabeth Strutzmann
CZChristina Zankl
Christina Zankl
TATiziana Adage
Tiziana Adage
MHMathias Heikenwalder
Mathias Heikenwalder
LBLubor Borsig
Lubor Borsig
The CCL2-CCR2 chemokine axis has an important role in cancer progression where it contributes to metastatic dissemination of several cancer types (e.g., colon, breast, prostate). Tumor cell–derived CCL2 was shown to promote the recruitment of CCR2+/Ly6Chi monocytes and to induce vascular permeability of CCR2+ endothelial cells in the lungs. Here we describe a novel decoy protein consisting of a CCL2 mutant protein fused to human serum albumin (dnCCL2-HSA chimera) with enhanced binding affinity to glycosaminoglycans that was tested in vivo. The monocyte-mediated tumor cell transendothelial migration was strongly reduced upon unfused dnCCL2 mutant treatment in vitro. dnCCL2-HSA chimera had an extended serum half-life and thus a prolonged exposure in vivo compared with the dnCCL2 mutant. dnCCL2-HSA chimera bound to the lung vasculature but caused minimal alterations in the leukocyte recruitment to the lungs. However, dnCCL2-HSA chimera treatment strongly reduced both lung vascular permeability and tumor cell seeding. Metastasis of MC-38GFP, 3LL, and LLC1 cells was significantly attenuated upon dnCCL2-HSA chimera treatment. Tumor cell seeding to the lungs resulted in enhanced expression of a proteoglycan syndecan-4 by endothelial cells that correlated with accumulation of the dnCCL2-HSA chimera in the vicinity of tumor cells. These findings demonstrate that the CCL2-based decoy protein effectively binds to the activated endothelium in lungs and blocks tumor cell extravasation through inhibition of vascular permeability.

1 December 2015 in Cytokine
Verified
Journal Article
Closed access
TATiziana Adage
Tiziana Adage
FBFrancesca del Bene
Francesca del Bene
FFFrancesco Fiorentini
Francesco Fiorentini
RDRobert P. Doornbos
Robert P. Doornbos
CZChristina Zankl
Christina Zankl
AKAndreas Kungl
Andreas Kungl

1 July 2016 in Neuroscience Letters
Verified
Journal Article
Closed access
MGMartha Gschwandtner
Martha Gschwandtner
APAnna Maria Piccinini
Anna Maria Piccinini
TGTanja Gerlza
Tanja Gerlza
TATiziana Adage
Tiziana Adage
AKAndreas Kungl
Andreas Kungl

1 February 2020 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
SBSimon H. Bayerl
Simon H. Bayerl
AGAdnan Ghori
Adnan Ghori
MNMelina Nieminen-Kelhä
Melina Nieminen-Kelhä
TATiziana Adage
Tiziana Adage
JBJörg Breitenbach
Jörg Breitenbach
VPVincent Prinz
Vincent Prinz
OBJECTIVE: The management of patients with aneurysmal subarachnoid hemorrhage (aSAH) remains a highly demanding challenge in critical care medicine. Despite all efforts, the calcium channel antagonist nimodipine remains the only drug approved for improving outcomes after aSAH. However, in its current form of application, it provides less than optimal efficacy and causes dose-limiting hypotension in a substantial number of patients. Here, the authors tested in vitro the release dynamics of a novel formulation of the calcium channel blocker nicardipine and in vivo local tolerance and tissue reaction using a chronic cranial window model in mice.METHODS: To characterize the release kinetics in vitro, dissolution experiments were performed using artificial cerebrospinal fluid over a time period of 21 days. The excipients used in this formulation (NicaPlant) for sustained nicardipine release are a mixture of two completely degradable polymers. A chronic cranial window in C57BL/6 mice was prepared, and NicaPlant slices were placed in proximity to the exposed cerebral vasculature. Epifluorescence video microscopy was performed right after implantation and on days 3 and 7 after surgery. Vessel diameter of the arteries and veins, vessel permeability, vessel configuration, and leukocyte–endothelial cell interaction were quantified by computer-assisted analysis. Immunofluorescence staining was performed to analyze inflammatory reactions and neuronal alterations.RESULTS: In vitro the nicardipine release profile showed an almost linear curve with about 80% release at day 15 and full release at day 21. In vivo epifluorescence video microscopy showed a significantly higher arterial vessel diameter in the NicaPlant group due to vessel dilatation (21.6 ± 2.6 µm vs 17.8 ± 1.5 µm in controls, p < 0.01) confirming vasoactivity of the implant, whereas the venous diameter was not affected. Vessel dilatation did not have any influence on the vessel permeability measured by contrast extravasation of the fluorescent dye in epifluorescence microscopy. Further, an increased leukocyte–endothelial cell interaction due to the implant could not be detected. Histological analysis did not show any microglial activation or accumulation. No structural neuronal changes were observed.CONCLUSIONS: NicaPlant provides continuous in vitro release of nicardipine over a 3-week observation period. In vivo testing confirmed vasoactivity and lack of toxicity. The local application of this novel nicardipine delivery system to the subarachnoid space is a promising tool to improve patient outcomes while avoiding systemic side effects.

1 March 2020 in Cytokine
Verified
Journal Article
Closed access
TGT. Gerlza
T. Gerlza
CTC. Trojacher
C. Trojacher
DJD. Jeremic
D. Jeremic
EKE. Krieger
E. Krieger
TATiziana Adage
Tiziana Adage
AKAndreas Kungl
Andreas Kungl